Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin that has bactericidal activity exclusively against gram-positive bacteria. Telavancin inhibits cell wall synthesis and disrupts cell membrane integrity.
Telavancin is active against gram-positive bacteria such as
Telavancin is used for complicated skin and skin structure infections as well as for hospital-acquired and ventilator-acquired bacterial pneumonia caused by sensitive isolates of S. aureus. Outcome may be worse for patients with baseline moderate to severe renal insufficiency.
Common adverse effects include
Telavancin also interferes with certain coagulation and urine protein assays.
Significant adverse effects include
Pruritus and flushing can be prevented by infusing the drug over ≥ 60 min.
QTc prolongation occurred in healthy subjects in the clinical trials of telavancin; thus, telavancin should be used with caution or not be used in patients taking drugs that prolong the QT interval. Telavancin should not be used in patients with congenital long QT syndrome, known QTc prolongation, uncompensated heart failure, or severe left ventricular hypertrophy (patients with these disorders were excluded from the clinical trials).